| 1408 |
National Cancer Institute |
Html |
en |
Grief, Bereavement, and Coping With Loss (PDQ®)–Health Professional Version |
Expert-reviewed report about grief, bereavement, and feelings of loss in survivors of someone who has died of cancer. Grief in children is also discussed. |
| normal grief process | 0.581221 |
| unanticipated grief | 0.551516 |
| IPT | 0.463911 |
| depressive symptoms | 0.559773 |
| loss | 0.542758 |
| common emotional reactions | 0.45155 |
| children | 0.526047 |
| interpersonal problems | 0.458662 |
| middle phase | 0.464448 |
| Health care providers | 0.455228 |
| grief counseling exists. | 0.565426 |
| grief | 0.933904 |
| anticipatory grief | 0.744484 |
| health care professionals | 0.481565 |
| unanticipated death differs | 0.464542 |
| exposure therapy | 0.455194 |
| bereaved people | 0.453892 |
| grief experiences | 0.564377 |
| grief reactions | 0.683036 |
| minimal grief reaction—a | 0.565 |
| age range | 0.479943 |
| grief symptoms | 0.544738 |
| deceased person | 0.466915 |
| grief intensity | 0.535236 |
|
| necessary grieving process | 0.451469 |
| social reactions | 0.450213 |
| select grief assessment | 0.557139 |
| normal grief | 0.697811 |
| death | 0.578011 |
| grief bursts | 0.548077 |
| IPT group | 0.456027 |
| cancer experience | 0.45206 |
| grieving process | 0.505158 |
| chronic grief reactions | 0.566742 |
| complicated grief | 0.62885 |
| term anticipatory grief | 0.59229 |
| health care | 0.509332 |
| common grief reactions | 0.572313 |
| pathologic grief reactions | 0.569264 |
| normal emotional process | 0.454248 |
| bereaved persons | 0.498553 |
| severe grief reactions | 0.591257 |
| grief disorder | 0.543808 |
| actual death | 0.478188 |
| grief treatment | 0.548186 |
| bereaved persons experience | 0.472239 |
| grief experience | 0.541082 |
| stage models | 0.450278 |
|
CLICK HERE |
| 1484 |
National Cancer Institute |
Html |
en |
Pituitary Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of pituitary tumors. |
| treatment | 0.39139 |
| diagnostic imaging choice | 0.347546 |
| magnetic resonance imaging | 0.340677 |
| pituitary tumors | 0.690926 |
| pituitary adenomas | 0.92392 |
| medical therapy exists. | 0.351515 |
| pituitary lesion | 0.527537 |
| transsphenoidal microsurgical approach | 0.343275 |
| visual field | 0.394767 |
| cell-type specific presentations | 0.354594 |
| medical therapy | 0.38784 |
| pituitary gland | 0.541344 |
| gonadotroph adenomas | 0.356536 |
| important clinical presentation | 0.355104 |
| pituitary carcinomas | 0.731658 |
| useful diagnostic tool | 0.338617 |
| inactive pituitary adenomas | 0.650057 |
| endocrine-inactive adenomas | 0.359468 |
| pituitary adenoma | 0.802139 |
| pituitary apoplexy | 0.612406 |
| hormone-producing adenomas | 0.35841 |
| Conventional radiation therapy | 0.361094 |
| functional criteria | 0.339781 |
| GH-receptor antagonists | 0.338498 |
|
| adjunctive radiation therapy | 0.355238 |
| MRI scan | 0.341418 |
| effective medical treatment | 0.350208 |
| pituitary disorders | 0.546502 |
| appropriately selected patients | 0.348512 |
| dopamine analogues | 0.357798 |
| pituitary tumor | 0.625147 |
| Sagittal T1-weighted images | 0.340975 |
| patients | 0.403665 |
| surgically high-risk patients | 0.358813 |
| adjunctive medical therapy | 0.353866 |
| Hormone-secreting pituitary carcinomas | 0.652967 |
| significant suprasellar extension | 0.453203 |
| safe surgical treatment | 0.370545 |
| gross total tumor | 0.361957 |
| surgical management | 0.338442 |
| pituitary adenoma literature | 0.647061 |
| pituitary neoplasms | 0.533177 |
| postoperative radiation therapy | 0.355824 |
| radiation therapy | 0.637553 |
| somatostatin analogues | 0.402133 |
| ergot-derived dopamine agonists | 0.339339 |
| pituitary tumors. | 0.521498 |
|
CLICK HERE |
| 1525 |
National Cancer Institute |
Html |
en |
Prostate Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of prostate cancer. |
| Gleason score | 0.479579 |
| stage II prostate | 0.274733 |
| prostate gland | 0.299389 |
| Digital rectal exam | 0.35449 |
| body | 0.293669 |
| advanced prostate cancer | 0.31933 |
| PDQ cancer information | 0.312303 |
| clinical trial search | 0.317203 |
| PSA level | 0.375326 |
| clinical trials | 0.630272 |
| metastatic prostate cancer | 0.326945 |
| cancer information summary | 0.293408 |
| clinical trial | 0.478353 |
| prostate cancer cells | 0.379555 |
| patients | 0.279925 |
| stage III prostate | 0.274165 |
| radiation therapy | 0.706978 |
| beam radiation therapy | 0.284995 |
| radioactive seeds | 0.279855 |
| Recurrent prostate cancer | 0.344704 |
| treatment | 0.475447 |
| prostate biopsy | 0.278369 |
| magnetic resonance imaging | 0.29143 |
| general information | 0.285325 |
| NCI-supported cancer | 0.281722 |
|
| cancer cells | 0.470422 |
| standard radiation therapy | 0.280665 |
| radical prostatectomy | 0.336986 |
| treatment clinical trials | 0.285008 |
| radioactive material | 0.277278 |
| National Cancer Institute | 0.336961 |
| Prostate Cancer Treatment | 0.329429 |
| high-intensity–focused ultrasound therapy | 0.287706 |
| hormone therapy | 0.461026 |
| benign prostatic hyperplasia | 0.328811 |
| new treatment | 0.295081 |
| external radiation therapy | 0.479863 |
| stage IV prostate | 0.27349 |
| prostate cancer | 0.898521 |
| cancer clinical trials | 0.332604 |
| prostate surgery | 0.277806 |
| prostate cancer surgery | 0.324678 |
| internal radiation therapy | 0.335143 |
| high PSA level | 0.327595 |
| cancer | 0.953437 |
| information | 0.335184 |
| standard treatment | 0.325661 |
| early-stage prostate cancer | 0.320186 |
| Transrectal ultrasound | 0.294546 |
|
CLICK HERE |
| 1999 |
National Cancer Institute |
Html |
es |
Tratamiento de los astrocitomas infantiles (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los astrocitomas infantiles. |
| siguientes procedimientos | 0.509449 |
| células madre | 0.756546 |
| siguientes aspectos | 0.541249 |
| efectos secundarios meses | 0.505608 |
| sustancia llamada fcev | 0.432048 |
| prueba mib-1 | 0.42502 |
| vÃa oral | 0.416944 |
| encéfalo benignos | 0.476825 |
| único tratamiento | 0.445679 |
| proteÃna cinasa.Los inhibidores | 0.434623 |
| glioma coroideo | 0.430143 |
| escasas ocasiones | 0.429534 |
| células t | 0.452739 |
| efectos tardÃos | 0.580441 |
| estrella llamadas | 0.429847 |
| PDQ Efectos tardÃos | 0.459317 |
| National Cancer Institute | 0.412326 |
| tumores benignos | 0.512758 |
| siguientes riesgos | 0.412382 |
|
| alto recién | 0.437854 |
| Instituto Nacional | 0.422716 |
| PDQ Tratamiento | 0.437378 |
| determinados cambios | 0.429353 |
| neurofibromatosis tipo | 0.592389 |
| tanta cantidad | 0.426418 |
| presente sección | 0.412644 |
| nuevos tipos | 0.4212 |
| siguientes casos | 0.43033 |
| sistema nervioso central | 0.991625 |
| Physician Data Query | 0.447246 |
| siguientes partes | 0.443422 |
| cuánto tumor | 0.508299 |
| cuerpo.ampliar derivación | 0.416932 |
| células cancerosas.Hay | 0.455449 |
| panel derecho | 0.460499 |
| siguientes sumarios | 0.465245 |
| vasos sanguÃneos | 0.616892 |
|
CLICK HERE |
| 2062 |
National Cancer Institute |
Html |
es |
Exámenes para detectar el cáncer colorrectal y los pólipos |
Hoja informativa que describe las ventajas y desventajas de varios exámenes selectivos de detección del cáncer colorrectal. |
| fecal usa anticuerpos | 0.492705 |
| screening flexible sigmoidoscopy | 0.428806 |
| colonography without | 0.411418 |
| alta sensibilidad | 0.434525 |
| Screening colonoscopy | 0.418332 |
| colorectal-cancer screening | 0.417889 |
| Circulating tumour markers | 0.417801 |
| Schoen RE | 0.427721 |
| randomized controlled trials | 0.418478 |
| historial médico | 0.412157 |
| rectal cancers | 0.41141 |
| define patients with | 0.416784 |
| personas morirán | 0.419825 |
| flexible sigmoidoscopy screening | 0.425333 |
| seguro médico | 0.427103 |
| Preventive Services Task | 0.418828 |
| digital rectal examination | 0.417389 |
| bario ayuda | 0.41421 |
| prueba adn-fit | 0.46424 |
| pequeñas cantidades | 0.431615 |
| prospective evaluation | 0.428506 |
| Internal Medicine | 0.490577 |
| materia fecal usa | 0.61279 |
| Estados Unidos | 0.627755 |
| PubMed Abstract | 0.909181 |
|
| única prueba | 0.462783 |
| fecal occult blood | 0.543844 |
| sangre llamada | 0.43281 |
| versus fecal occult | 0.484081 |
| Noninvasive testing | 0.410836 |
| computed tomographic colonography | 0.451989 |
| principales factores | 0.410616 |
| prospective multicenter study | 0.41765 |
| regular —por ejemplo | 0.423251 |
| General Internal Medicine | 0.422201 |
| Servicios Preventivos | 0.435789 |
| controlled trial | 0.42874 |
| PLoS Medicine | 0.414525 |
| methylated sept9 | 0.411171 |
| riesgo promedio | 0.720816 |
| fecal immunochemical testing | 0.480317 |
| Affairs Cooperative Study | 0.41697 |
| computadora ensambla | 0.410696 |
| llamada dcbe | 0.410601 |
| llamada fit | 0.414186 |
| pequeño riesgo | 0.422784 |
| cuáles pruebas | 0.470698 |
| necesarios procedimientos | 0.459521 |
| New England Journal | 0.448594 |
|
CLICK HERE |
| 3597 |
National Cancer Institute |
Html |
en |
MERIT Award Recipient: Laimonis A. Laimins, Ph.D. |
MERIT Award Recipient: Laimonis A. Laimins, Ph.D. |
| productive life cycle | 0.692492 |
| anti-viral therapies | 0.414992 |
| long-term objective | 0.415026 |
| viral particles | 0.475434 |
| viral factor | 0.465899 |
| HPV types | 0.533205 |
| Viral infection | 0.48447 |
| HPV proteins functions | 0.60071 |
| proliferative lesions | 0.427068 |
| stratified epithelial cells | 0.554619 |
| E4 protein | 0.416206 |
| small DNA viruses | 0.509754 |
| development | 0.367942 |
| life cycle | 0.732336 |
| tissue culture | 0.408683 |
| cervical cancer | 0.697893 |
| anogenital cancers | 0.416749 |
| viral replication | 0.470226 |
| pathogenesis | 0.323941 |
| certain types | 0.427907 |
| late viral functions | 0.551387 |
| HPV functions | 0.507234 |
| genetic analyses | 0.407346 |
| HPV infections | 0.62415 |
| activation | 0.321394 |
|
| productive viral life | 0.570807 |
| blocks infection | 0.430045 |
| E5 protein | 0.409072 |
| differentiation | 0.394198 |
| HPVs | 0.330868 |
| methods | 0.33537 |
| virion assembly | 0.42345 |
| genome amplification | 0.41342 |
| human papillomaviruses | 0.908593 |
| Oncogenic Papillomaviruses | 0.574563 |
| organotypic cultures | 0.4081 |
| normal cells | 0.43284 |
| suprabasal cells | 0.432461 |
| cases | 0.370169 |
| effective anti-virals | 0.431518 |
| epithelial cells | 0.561264 |
| protein synthesis | 0.412779 |
| HPV viral proteins | 0.658868 |
| vaccine | 0.388142 |
| Additional studies | 0.403147 |
| future | 0.32145 |
| cell death pathway | 0.503149 |
| high-risk types | 0.424894 |
| grant | 0.339966 |
|
CLICK HERE |
| 15632 |
National Cancer Institute |
Html |
null |
NCI Grant Application Development, Submission, and Award |
Learn how the six-step process of the NCI grants process works— from application development, to peer review, to post-award administration. |
|
|
CLICK HERE |
| 16844 |
National Cancer Institute |
Html |
en |
Ohio State University and University of Kentucky — Optimizing RNA Nanoparticle's Size and Shape for Enhancing Cancer Targeting and Treatment |
A systematic characterization of RNA nanoparticle behavior, in vitro and in vivo, to optimize its cellular delivery to triple negative breast cancer (TNBC). |
| optimized therapeutic systems | 0.528757 |
| varying shapes | 0.305417 |
| moieties | 0.241586 |
| endosomal escape | 0.300775 |
| RNA nanoparticle behavior | 0.817424 |
| optimum shape | 0.346242 |
| project team | 0.300326 |
| vivo delivery | 0.345174 |
| overall goal | 0.318652 |
| therapeutic components | 0.373072 |
| Jianhua Yu | 0.345836 |
| tumor regression | 0.318722 |
| Enhancing Cancer Targeting | 0.687284 |
| William Carson | 0.342459 |
| internalization/intracellular trafficking | 0.315312 |
| efficient therapeutic delivery | 0.542327 |
| surgical oncology | 0.297773 |
|
| delivery systems | 0.312116 |
| pharmacokinetic profiles | 0.331727 |
| Daniel Pack | 0.340086 |
| Ohio State University | 0.5489 |
| nanoparticle size | 0.433341 |
| gene therapy | 0.299174 |
| RNA nanoparticles | 0.513535 |
| negative breast cancer | 0.501323 |
| facile chemical processing | 0.476016 |
| rna nanoparticle | 0.954079 |
| Principal Investigators | 0.353961 |
| Peixuan Guo | 0.400645 |
| favorable biodistribution | 0.529957 |
| molecular / cell | 0.296003 |
| cancer immunotherapy | 0.325509 |
| systematic studies | 0.315425 |
| systematic characterization | 0.33975 |
|
CLICK HERE |
| 16863 |
National Cancer Institute |
Html |
es |
Selected Vegetables y Sun's Soup (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de Selected Vegetables y Sun's Soup como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.402144 |
| pequeño número | 0.40122 |
| estadio iv | 0.404103 |
| New Hampshire Avenue | 0.401505 |
| Drug Administration | 0.400937 |
| Sun’s Soup | 0.535838 |
| NCI Best Case | 0.4027 |
| Sun's Soup | 0.648887 |
| Selected Vegetables | 0.997532 |
| mezcla original hongos | 0.402938 |
| fitoquÃmicos anticancerÃgenos | 0.401555 |
| Freeze-dried Selected Vegetables | 0.409927 |
| datos bibliográficos pubmed | 0.401627 |
| siguientes ingredientes | 0.401955 |
| siguientes preguntas | 0.400938 |
| cuerpo usa | 0.401378 |
| Dátil rojo | 0.401496 |
| siguientes riesgos | 0.401219 |
| Scutellaria barbata | 0.401858 |
|
| Instituto Nacional | 0.408304 |
| Salud Complementaria | 0.403343 |
| Visuals Online | 0.401103 |
| siguientes versiones | 0.401582 |
| complementarias revisa | 0.401573 |
| Physician Data Query | 0.406378 |
| personas enfermas | 0.401456 |
| Estados Unidos | 0.461182 |
| libre uso | 0.401151 |
| mezcla contenÃa hongos | 0.402782 |
| efectos secundarios dañinos | 0.402436 |
| página manejo | 0.401027 |
| ¿El tratamiento | 0.402145 |
| ¿Los beneficios | 0.40095 |
| juntos cam | 0.400907 |
| hierbas hedyotis | 0.40184 |
| Series Program | 0.400934 |
| medicina complementaria | 0.443276 |
|
CLICK HERE |
| 17231 |
National Cancer Institute |
Html |
es |
Secuenciación del ADN de tumores en el tratamiento de cáncer |
null |
| mutaciones impulsoras | 0.72633 |
| Investigación ClÃnica Proteómica | 0.72046 |
| MATCH Infantil | 0.761796 |
| máquina llamada secuenciador | 0.847349 |
| llamada secuenciación | 0.960353 |
|
| Darryl Leja | 0.794924 |
| gen egfr | 0.773791 |
| llamadas paneles | 0.73634 |
| mayorÃa surgen | 0.7646 |
|
CLICK HERE |